Substance Use Disorder

President Trump signed into law HR 2483, also known as the SUPPORT for Patients and Communities Reauthorization Act of 2025.

Jeffrey Bratberg, PharmD, BCPS, and Michelle Caetano, PharmD, BCACP, CVDOE, CDOE, BCPT, discuss the Pharmacy Bridge resource and pharmacists’ role in OUD management.

Researchers explore OTC naloxone sales sold independently at pharmacies and programmatically from 2023 to 2024.

Researchers explore whether or not exposure to e-cigarette or cannabis content on social media leads to increased use among adolescents.

Researchers identified differences in naloxone training, policies, procedures, and preferences among chain or independent pharmacies across Alabama.

Haley Pals, PharmD, BCPP, and Thomas Franko, PharmD, discussed the best approaches in the use of buprenorphine for treating patients with SUD.

The top reported barriers to providing buprenorphine included regulatory and administrative, operational and attitudinal, and patient-related challenges.

Researchers conducted a cross-sectional study to investigate the accessibility of over-the-counter naloxone and nonprescription syringes at community pharmacies.

A dose response is observed with the highest dose of the drug and mitigating withdrawal symptoms for patients with cannabis use disorder.

The lawsuit alleges that the company knowingly violated both the Controlled Substances Act and the False Claims Act.

AMA released its 2024 Overdose Epidemic Report and presented key findings from the past year.

The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.

As health care systems and the current syndemic continue to evolve, pharmacies are poised to play a crucial role in improving public health.

Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Sara T. Thomason discuses the impact of stigma on pharmacists who are dealing with substance use disorder, the importance of mental health care, and how schools support pharmacy students dealing with addiction.

Investigators used electronic health record data to compare outcomes of semaglutide vs other antidiabetic medications.

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

Independent pharmacists, health care providers, community leaders, and law enforcement must all work together to address the fentanyl epidemic.

Community pharmacies in counties with high racialized economic segregation had higher odds of restricting buprenorphine.

Nalmefene injection is an opioid receptor antagonist and comes in a single-dose, pre-filled auto-injector that delivers 1.5 mg of the medication per actuation.

The study’s mixed findings on telehealth for opioid use disorder (OUD) treatment suggest a need for more individualized approaches to care.

A study found that cannabis use increased the risk of hospitalization and intensive care unit admission following a COVID-19 diagnosis.

Check out these top featured stories from Drug Topics in June 2024.